Antivenom Serum

PreclinicalSmall molecule

GGuangzhou Institute of Respiratory Disease

Antivenom Serum is one of 30 small molecule programs targeting Skin Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin InfectionActive, not recruiting

Skin InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Skin Infection

#DrugCompanyPhaseTrials

Keflex

Eli Lilly

Approved

2 2

Omnicef

AbbVie

Approved

1 3

Vancocin

HHikma Pharmaceuticals LLC

Approved

6 4

Lotrimin

Bayer

Approved

—5

Cubicin

BBaxter Healthcare Corporation

Approved

4 6

Tygacil

PPrism Pharmaceuticals

Approved

2 7

Betadine

BBecton, Dickinson and Company

Teflaro

3 9

Levaquin

WWim Janssens

Phase 3

1 10

Ampicillin-Sulbactam

Pfizer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Skin Infection1 trial

Predictive Modeling of Necrotizing Skin Infections in Snakebite Patients

Completed·GGuangzhou Institute of Respiratory Disease··NCT06622343·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antivenom Serum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antivenom Serum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antivenom Serum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Institute of Respiratory Disease company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou Institute of Respiratory Disease

Antivenom Serum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Skin Infection1 trial

References

Drug Info

Quick Facts

Related News